What is a stock summary page? Click here for an overview.
Business Description
Quince Therapeutics Inc
NAICS : 325412
SIC : 2836
ISIN : US22053A1079
Description
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.75 | |||||
| Equity-to-Asset | 0.26 | |||||
| Debt-to-Equity | 0.49 | |||||
| Debt-to-EBITDA | -0.41 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 35 | |||||
| 3-Year EPS without NRI Growth Rate | 32.7 | |||||
| 3-Year FCF Growth Rate | 29.5 | |||||
| 3-Year Book Growth Rate | -44.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.16 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.33 | |||||
| 9-Day RSI | 31.56 | |||||
| 14-Day RSI | 35.34 | |||||
| 3-1 Month Momentum % | -24.62 | |||||
| 6-1 Month Momentum % | 86.43 | |||||
| 12-1 Month Momentum % | 41.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.05 | |||||
| Quick Ratio | 6.05 | |||||
| Cash Ratio | 5.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.5 | |||||
| Shareholder Yield % | -20.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -101.01 | |||||
| ROA % | -40.42 | |||||
| ROIC % | -44.01 | |||||
| 3-Year ROIIC % | 111.83 | |||||
| ROC (Joel Greenblatt) % | -4747.97 | |||||
| ROCE % | -27.38 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.78 | |||||
| EV-to-EBIT | -0.77 | |||||
| EV-to-Forward-EBIT | -0.77 | |||||
| EV-to-EBITDA | -0.77 | |||||
| EV-to-Forward-EBITDA | -0.01 | |||||
| EV-to-FCF | -0.86 | |||||
| Earnings Yield (Greenblatt) % | -129.87 | |||||
| FCF Yield % | -59.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:QNCX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Quince Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.31 | ||
| Beta | 1.13 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.34 | ||
| Volatility % | 120.85 | ||
| 14-Day RSI | 35.34 | ||
| 14-Day ATR ($) | 0.101106 | ||
| 20-Day SMA ($) | 1.3665 | ||
| 12-1 Month Momentum % | 41.35 | ||
| 52-Week Range ($) | 0.5116 - 2.45 | ||
| Shares Outstanding (Mil) | 44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Quince Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Quince Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Quince Therapeutics Inc Frequently Asked Questions
What is Quince Therapeutics Inc(QNCX)'s stock price today?
The current price of QNCX is $1.22. The 52 week high of QNCX is $2.45 and 52 week low is $0.51.
When is next earnings date of Quince Therapeutics Inc(QNCX)?
The next earnings date of Quince Therapeutics Inc(QNCX) is 2025-05-13 Est..
Does Quince Therapeutics Inc(QNCX) pay dividends? If so, how much?
Quince Therapeutics Inc(QNCX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers